Sun Pharma Q2 profit beats estimates on strong India demand

Sun Pharmaceutical Industries, India’s largest drugmaker by revenue, reported a better-than-expected quarterly profit, powered by double-digit growth in its domestic business and robust demand across key therapeutic areas.

The Mumbai-based company’s consolidated net profit rose to ₹31.18 billion ($354.7 million) for the quarter ended September 30, compared with ₹30.4 billion a year earlier, surpassing analyst estimates of ₹29.97 billion. Revenue climbed 8.6% to ₹144.05 billion, aided by an 11% jump in India sales — its largest market.

While US revenue fell 4.1% to $496 million due to pricing pressure, analysts said Sun Pharma is well-positioned in that region thanks to new launches in alopecia and psoriasis treatments. Managing Director Kirti Ganorkar said the company aims for mid-to-high single-digit revenue growth this fiscal and plans to be among the first to launch semaglutide-based weight-loss drugs in India once patents expire in 2026.

Sun, one of the Indian drugmakers most exposed to the US market, also said it is open to expanding manufacturing there to counter potential tariff risks under President Donald Trump’s administration.